Tyme Technologies (TYME) Now Covered by Canaccord Genuity
Equities research analysts at Canaccord Genuity initiated coverage on shares of Tyme Technologies (NASDAQ:TYME) in a report released on Wednesday, Marketbeat.com reports. The firm set a “buy” rating on the stock.
Other equities research analysts have also recently issued reports about the company. HC Wainwright initiated coverage on Tyme Technologies in a report on Friday, December 15th. They set a “buy” rating and a $8.00 target price for the company. Evercore ISI initiated coverage on Tyme Technologies in a report on Friday, November 17th. They set an “outperform” rating and a $7.00 target price for the company.
Shares of Tyme Technologies (NASDAQ TYME) opened at $6.93 on Wednesday. The firm has a market capitalization of $618.99, a PE ratio of -40.76 and a beta of -0.01. Tyme Technologies has a fifty-two week low of $2.01 and a fifty-two week high of $9.50.
In other Tyme Technologies news, COO Michael Demurjian sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $3.34, for a total transaction of $167,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
About Tyme Technologies
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.